<DOC>
	<DOCNO>NCT00054158</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop cancer cell divide stop grow die . Thalidomide may stop growth cancer stop blood flow tumor . Combining chemotherapy thalidomide may kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy thalidomide treat patient newly diagnose stage I , stage II , stage III multiple myeloma .</brief_summary>
	<brief_title>Combination Chemotherapy Thalidomide Treating Patients With Stage I , Stage II , Stage III Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Determine overall response rate patient newly diagnose stage I , II , III multiple myeloma treat vincristine , doxorubicin , dexamethasone , low-dose thalidomide . - Determine ability collect peripheral blood stem cell patient treatment regimen . OUTLINE : This open-label , nonrandomized study . Patients receive vincristine IV doxorubicin IV continuously day 1-4 oral dexamethasone day 1-4 , 9-12 , 17-20 . Patients also receive low-dose oral thalidomide daily day 1-28 . Treatment repeat every 4 week 4-6 course absence disease progression . Patients follow disease progression bone marrow transplantation . PROJECTED ACCRUAL : Approximately 17-37 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose stage I , II , III multiple myeloma ( MM ) No refractory relapse MM PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin le 1.5 mg/dL AST le 2.5 time upper limit normal Renal Not specify Other Not pregnant nursing Negative pregnancy test Fertile patient must use 2 effective method contraception ( include least 1 highly active method ) least 4 week , , least 4 week study participation No active serious infection uncontrolled antibiotic No insufficient mental capacity would preclude informed consent No medical condition reason would preclude study participation Willing able comply FDAmandated S.T.E.P.S program PRIOR CONCURRENT THERAPY : Biologic therapy No prior thalidomide Chemotherapy No 1 course prior vincristine , doxorubicin , dexamethasone Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No concurrent alcohol consumption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>